ImmunityBio stock price crash: buy the dip or sell the rip?

ImmunityBio Inc (NASDAQ: IBRX) is under immense pressure on March 24 after the US Food and Drug Administration (FDA) issued a scathing warning letter over the firm’s promotional tactics.

Investors bailed on IBRX as regulators alleged the company and its billionaire founder, Dr. Patrick Soon-Shiong, used a TV ad and a high-profile podcast to make “false or misleading” claims about Anktiva.

The FDA specifically accused ImmunityBio of suggesting its flagship bladder cancer drug could “cure” or “prevent” all cancers; a claim lacking clinical backing and in violation of federal law.

Despite this sharp correction, IBRX shares remain one of 2026’s top performers, currently up some 250% versus the start of this year as markets continue to reward the firm’s explosive sales growth and international approvals.

Why is FDA warning bearish for ImmunityBio stock?

FDA’s intervention is a major blow to ImmunityBio stock as it strikes at the company’s credibility and regulatory standing.

Accusing the firm of misbranding Anktiva as a pan-cancer vaccine rather than its approved bladder cancer indication, the agency has signaled distrust in management’s communication practices.

This isn’t a minor marketing misstep – it’s a “formal violation” that may trigger financial penalties, stricter oversight, and delays in future drug applications.

Plus, IBRX lost about $351 million last year, which adds weight to the bearish case. Its Altman Z-Score of -5.91 points to distress-level risk if cash burn continues unchecked.

Insider selling, including director Barry J. Simon’s recent $1.78 million divestment, further weighs on sentiment. For cautious investors, all of this suggests “selling the rip” in ImmunityBio may be a more prudent approach in 2026.

Why IBRX shares may still be worth buying on the dip

On the flip side, exceptional top-line growth makes ImmunityBio shares more attractive as a long-term holding.

In 2025, the firm’s net product revenue soared 700% year-on-year to $113 million, driven mostly by the rapid adoption of Anktiva in the US market.

Importantly, the FDA hasn’t disputed the drug’s clinical profile for BCG-unresponsive bladder cancer, and its inclusion in the 2026 NCCN guidelines significantly expands its patient reach.

Liquidity remains solid as well, thanks to a $200 million term loan facility, supporting production scale-up.

Investors could also take heart in the fact that Wall Street remains bullish on IBRX for the next 12 months. 

The consensus rating on this biotech stock sits at “strong buy” currently, with the mean price target of nearly $15 suggesting it could more than double by year-end.

For investors with high risk tolerance, therefore, today’s dip may represent a rare entry point into a company with a proven product and expanding global footprint.

What to expect from ImmunityBio moving forward?

The long-term bull case rests on ImmunityBio’s evolution from a research-focused biotech into a global commercial powerhouse.

The company recently secured regulatory approval for Anktiva in “Macau” and now operates in a total of 33 countries.

A supplemental Biologics License Application (sBLA) filed with the FDA earlier this month could broaden Anktiva’s use, exponentially increasing its addressable market.

Strategically, IBRX stock could benefit from shortages of traditional bladder cancer treatments – filling a critical gap in oncology care.

Meanwhile, despite recent divestments, insider ownership remains “exceptionally high” at nearly 70%, aligning management’s interests with shareholders.

In short, if compliance concerns are swiftly addressed, ImmunityBio may rebound sharply, supported by a multi-billion-dollar oncology niche and a pipeline with potential beyond bladder cancer.